Estrella Immunopharma (ESLA) Long-Term Investments (2021 - 2024)

Estrella Immunopharma (ESLA) has reported Long-Term Investments for 4 consecutive years, with $45511.0 the latest figure, recorded in Q3 2024.

• In Q3 2024, Long-Term Investments fell 99.11% year-over-year to $45511.0; the TTM figure through Sep 2024 stood at $45511.0 (down 99.11% YoY), while the FY2024 annual figure was $45511.0, down 99.54% from the prior year.
• Long-Term Investments steadied at $45511.0 in Q3 2024 per ESLA's latest filing, from $45511.0 in the prior quarter.
• Across five years, Long-Term Investments topped out at $45.5 million in Q3 2022 and bottomed at $45511.0 in Q4 2023.
• Historically, Long-Term Investments has averaged $20.1 million across 4 years, with a median of $9.7 million in 2023.
• Annual changes were most pronounced in 2022 — Long-Term Investments grew 0.6% — and 2024, when it sank 99.54%.
• Estrella Immunopharma's Long-Term Investments stood at $45.2 million in 2021, then sank by 78.6% to $9.7 million in 2022, then slumped by 99.53% to $45511.0 in 2023, then changed by 0.0% to $45511.0 in 2024.
• Business Quant data shows ESLA's Long-Term Investments at $45511.0 in Q3 2024, $45511.0 in Q2 2024, and $45511.0 in Q1 2024.